Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Retained Earnings · Q3 FY2026 · quarter ended Aug 2026

Retained earnings remains negative

Q3 FY2026 retained earnings was -$630.13M, compared with -$925.01M a year earlier.

Context

  • Retained earnings amounted to 52.7% of total assets at the end of Q3 FY2026, down 124.3 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps rising in the next quarterly balance sheet after a +31.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterAug 2026
-$630.13M+46.6% QoQ
Last fiscal yearNov 2025
-$1B-35.8% YoY
Year agoAug 2025
-$925.01M+31.9% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+31.9%——
1 year-35.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1B) USD
Year-over-year change
-35.8%

Retained Earnings vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's Aug 2026 retained earnings of -$630.13M is the highest of the 8 companies compared; the peer median is -$1.2B.
  • Its year-over-year change of +31.9% is the highest of 8, against a peer median of -30.9%.
  • Retained earnings amounts to 52.7% of total assets for NRIX, versus a peer median of 191.2%.
NRIX Competitors Peer median
Retained Earnings for NRIX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NRIXNurix Therapeutics, Inc.Aug 2026-$630.13M +31.9%—52.7%
CCCCC4 Therapeutics, Inc.Mar 2026-$763.82M -15.7%—232.3%
TNGXTango Therapeutics, Inc.Sep 2026-$772.4M -36.9%—74.7%
RIGLRigel Pharmaceuticals, Inc.Mar 2026-$1.01B +26.4%—201.0%
KYMRKymera Therapeutics, Inc.Jun 2026-$1.2B -33.4%—72.7%
KURAKura Oncology, Inc.Mar 2026-$1.25B -30.9%—191.2%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026-$1.55B -18.6%—327.8%
RVMDRevolution Medicines, Inc.Jun 2026-$3.97B -80.4%—91.8%
Peer median (excluding NRIX) -$1.2B-30.9%—191.2%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Cash & Equivalents80.51M64.47M54.63M110M246.96M
Short-term Investments215.21M244.67M233.28M499.59M345.98M
Net Receivables6.2M1.1M800K1.5M0
Inventory0(1.1M)000
Other Current Assets900K9.31M6.8M8.3M13.88M
Total Current Assets311.12M318.45M295.5M619.39M606.82M
Property, Plant & Equipment (Net)25.35M29.51M47.95M45.9M73.01M
Goodwill00000
Intangible Assets00000
Long-term Investments137.48M63.88M7.42M00
Tax Assets00000
Other Non-current Assets3.12M4.92M4.72M4.06M8.31M
Total Non-current Assets165.65M98.31M60.1M49.96M81.32M
Total Assets476.77M416.76M355.6M669.34M688.14M
Account Payables6.65M5.06M6.4M11.48M11.22M
Short-term Debt3.85M5.53M7.49M00
Tax Payables75K85K30K1.24M0
Deferred Revenue41.21M37.63M48.1M38.36M17.58M
Other Current Liabilities5.67M9.14M751K18.91M23.64M
Total Current Liabilities66.26M70.66M86.96M95.85M86.47M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)59.02M35.97M45.02M26.21M10.01M
Other Non-current Liabilities00000
Total Non-current Liabilities68.21M42.41M68.15M46.5M62.92M
Total Liabilities134.47M113.06M155.11M142.35M149.39M
Common Stock45K47K49K76K102K
Retained Earnings(220.89M)(401.25M)(545.2M)(738.77M)(1B)
Accumulated OCI(608K)(4.32M)(655K)150K105K
Other Stockholders Equity00000
Minority Interest00000
Total Equity342.3M303.7M200.49M526.99M538.75M
Total Debt13.04M11.96M30.61M28.3M55.73M
Net Debt(67.47M)(52.51M)(24.01M)(81.69M)(191.23M)

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.